Eric Lefkofsky is well known as the co-founder of the largest online platform that connects customers with wide range of merchants across the country, Groupon. He is one of the billionaires who can easily spend time enjoying his hard work. Groupon was his first love, but his priority has changed over the years. His wife was diagnosed with breast cancer a few years ago, and he was unable to find relevant information or data on cancer studies. It was then he realized that finding information on cancer was a big problem and he had to do something about it. It was then that he started working on a new company and started Tempus.
Tempus is a technology company that will offer a data system helping connect molecular and anatomic data with clinical data from the various medical facilities in the country. The company will help doctors and those with medical backgrounds to find all the historic results right at one place to be able to take a better decision regarding cancer treatments. The chemo and the amount of radiation given to the cancer patients can be easily adjusted if the doctors have the historic results from other patients with similar genetic make-up in front of them. Lefkofsky at Facebook .
Many health centers have already collaborated with Tempus to share their patient’s records with them. The latest one to be added to the list is the Ambramson Cancer Center of the University of Pennsylvania. Some other centers which have already collaborated with them are Rush University Medical Center, Lurie Comprehensive Cancer Center of the Northwestern University and many more. More Information Here .
In an interview, Eric Lefkofsky said that he does not expect quick results and this company will be a good start to attach technology with cancer and to provide better health care to cancer patients in the country. Being a privately held company, Lefkofsky says that since he will not have to answer to shareholders, the company can do some great work and ensure that it benefits those who need it. The doctors can have a comprehensive data system to take better treatment decisions and to keep more people with cancer alive and thriving.